EMMA (Emmaus Life Sciences) FCF Margin %: -17.36% (As of Mar. 2026)


What is Emmaus Life Sciences FCF Margin %?

Emmaus Life Sciences EMMA -16.67% FCF Margin % is -17.36% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 960 Biotechnology companies, Emmaus Life Sciences ranks better than 71.35% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Emmaus Life Sciences's Free Cash Flow for the three months ended in Mar. 2026 was $-0.34 Mil. Emmaus Life Sciences's Revenue for the three months ended in Mar. 2026 was $1.98 Mil. Therefore, Emmaus Life Sciences's FCF Margin % for the quarter that ended in Mar. 2026 was -17.36%.

As of today, Emmaus Life Sciences's current FCF Yield % is -90.31%.

The historical rank and industry rank for Emmaus Life Sciences's FCF Margin % or its related term are showing as below:

EMMA' s FCF Margin % Range Over the Past 10 Years
Min: -3815.5   Med: -16.97   Max: -0.1
Current: -5.27

During the past 13 years, the highest FCF Margin % of Emmaus Life Sciences was -0.10%. The lowest was -3815.50%. And the median was -16.97%.

EMMA's FCF Margin % is ranked better than
71.35% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs EMMA: -5.27

Emmaus Life Sciences FCF Margin % Related Terms

Emmaus Life Sciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences FCF Margin % Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.44 -27.73 -5.14 -13.80 -0.10

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.60 -103.23 12.11 57.35 -17.36

EMMA vs CERO, AGTX, WINT: FCF Margin % Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's FCF Margin % falls into.


Emmaus Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Emmaus Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.012/12.453
=-0.10 %

Emmaus Life Sciences's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.344/1.982
=-17.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -17.36% mean?
Emmaus Life Sciences (EMMA) has a FCF Margin % of -17.36% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #275 out of 960 companies in the Biotechnology industry, placing it in the top 28.6%.
Is Emmaus Life Sciences' FCF Margin % too high?
Emmaus Life Sciences' current FCF Margin % is -17.36%. Based on the distribution chart, Emmaus Life Sciences ranks #275 out of 960 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' FCF Margin % compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #275 out of 960 companies for FCF Margin %. This puts Emmaus Life Sciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current FCF Margin % is -17.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current FCF Margin % is -17.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current FCF Margin % is -17.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.